The deal represents a significant strategic shift for CLVT as it monetizes its Life Sciences & Healthcare segment for ~35% of its current $1.7B market cap. Monitor regulatory clearances (HSR and foreign investment) as the key catalysts for closing, expected by end of 2026. The termination fee and Altaris parent guarantee reduce execution risk, but the deferred consideration and seller note structure suggest valuation may be discounted versus an all-cash premium.
Price Chart
Executive Summary
Clarivate PLC has signed a definitive agreement to sell its Life Sciences & Healthcare business to an affiliate of Altaris, LLC for a total consideration of $600 million, consisting of $500 million cash at close, $25 million deferred consideration, and a $75 million seller note. The transaction does not require shareholder approval and is expected to close by end of 2026, subject to regulatory approvals and customary conditions.
Key Financial Metrics
Key Facts
- Purchase price of $600 million: $500M cash, $25M deferred consideration, $75M seller note
- Buyer is an affiliate of Altaris, LLC (Janus Buyer LP)
- Transaction expected to close by end of calendar year 2026
- No shareholder vote required
- Termination fee of $33 million payable by Buyer in certain circumstances
- Retention agreement with President Henry Levy to encourage completion of the deal
- Clarivate retains its remaining businesses after the sale
Financial Impact
Total consideration of $600,000,000, with $500,000,000 cash at closing, $25,000,000 deferred consideration (payable by Jan 31, 2028), and a $75,000,000 senior unsecured PIK note due 2036
Risk Factors
- Regulatory approval process could delay or block the transaction
- Deal termination risk: $33M termination fee is small relative to deal size (~5.5% of base purchase price), creating some buyer-side optionality
- Post-close integration risks and potential revenue attrition from shared contracts
- Performance of retained businesses post-divestiture is unknown
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-010269 |
| Document: dp249688_8k.htm | 0000950103-26-010269 |
| Document: 0000950103-26-010269-index-headers.html | 0000950103-26-010269 |
| Document: 0000950103-26-010269-index.html | 0000950103-26-010269 |
| Document: 0000950103-26-010269.txt | 0000950103-26-010269 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K/A | $1.61 | awaiting T+20 | — | $1.87 (+16.15%) |
Oct 6, 2026 20d ago | 8-K | $1.47 | awaiting T+20 | — | $1.87 (+27.21%) |
Sep 24, 2026 4w ago | 8-K | $1.84 $1.85 | ▲ +0.54% | ▲ +0.96% | $1.87 (+1.63%) |
Sep 22, 2026 4w ago | Press Release | $1.89 $1.78 | ▼ −5.82% | ▼ −5.26% | $1.87 (−1.06%) |
Sep 17, 2026 5w ago | Press Release | $1.90 $1.74 | ▼ −8.42% | ▼ −9.88% | $1.87 (−1.58%) |
Aug 10, 2026 11w ago | Insider Cluster | $1.91 $1.91 | · 0.00% | ▲ +1.06% | $1.87 (−2.09%) |
Aug 3, 2026 12w ago | 144 | $1.97 $2.04 | ▼ −3.55% | ▼ −4.79% | $1.87 (+5.08%) |
Jul 6, 2026 16w ago | 8-K | $2.51 $1.94 | ▼ −22.71% | ▼ −24.04% | $1.87 (−25.50%) |
Jul 6, 2026 16w ago | 8-K | $2.44 $1.98 | ▼ −18.85% | ▼ −18.29% | $1.87 (−23.36%) |
Jun 8, 2026 20w ago | 8-K | $2.38 $2.51 | ▲ +5.46% | ▲ +4.02% | $1.87 (−21.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers